Evaluation

What best describes your current professional status? *

Private

Hospital

Academic

Other

I am a licensed Physician in the United States *

Yes

No

How many years have you been in practice? *

Approximately how many patients with Cystic Fibrosis do you typically see each month? *

How did you hear about this symposium? *

Please rate the extent to which the symposium met the following objectives *

Please use the scale: 1=Poor, 2=Fair, 3=Satisfactory, 4=Good, 5=Excellent

	1	2	3	4	5
Discuss novel diagnostic strategies, updated guidelines, and the principles of precision medicine for the cystic fibrosis patient	Discuss novel diagnostic strategies, updated guidelines, and the principles of precision medicine for the cystic fibrosis patient - 1	Discuss novel diagnostic strategies, updated guidelines, and the principles of precision medicine for the cystic fibrosis patient - 2	Discuss novel diagnostic strategies, updated guidelines, and the principles of precision medicine for the cystic fibrosis patient - 3	Discuss novel diagnostic strategies, updated guidelines, and the principles of precision medicine for the cystic fibrosis patient - 4	Discuss novel diagnostic strategies, updated guidelines, and the principles of precision medicine for the cystic fibrosis patient - 5
Analyze the improved disease progression in cystic fibrosis patients who have received CFTR modulation therapy	Analyze the improved disease progression in cystic fibrosis patients who have received CFTR modulation therapy - 1	Analyze the improved disease progression in cystic fibrosis patients who have received CFTR modulation therapy - 2	Analyze the improved disease progression in cystic fibrosis patients who have received CFTR modulation therapy - 3	Analyze the improved disease progression in cystic fibrosis patients who have received CFTR modulation therapy - 4	Analyze the improved disease progression in cystic fibrosis patients who have received CFTR modulation therapy - 5
Review the most current and emerging clinical trial data for CFTR modulation, as well as combination therapies, in the patient with cystic fibrosis	Review the most current and emerging clinical trial data for CFTR modulation, as well as combination therapies, in the patient with cystic fibrosis - 1	Review the most current and emerging clinical trial data for CFTR modulation, as well as combination therapies, in the patient with cystic fibrosis - 2	Review the most current and emerging clinical trial data for CFTR modulation, as well as combination therapies, in the patient with cystic fibrosis - 3	Review the most current and emerging clinical trial data for CFTR modulation, as well as combination therapies, in the patient with cystic fibrosis - 4	Review the most current and emerging clinical trial data for CFTR modulation, as well as combination therapies, in the patient with cystic fibrosis - 5
Optimize your strategies to manage and monitor CFTR modulator-treated cystic fibrosis patients	Optimize your strategies to manage and monitor CFTR modulator-treated cystic fibrosis patients - 1	Optimize your strategies to manage and monitor CFTR modulator-treated cystic fibrosis patients - 2	Optimize your strategies to manage and monitor CFTR modulator-treated cystic fibrosis patients - 3	Optimize your strategies to manage and monitor CFTR modulator-treated cystic fibrosis patients - 4	Optimize your strategies to manage and monitor CFTR modulator-treated cystic fibrosis patients - 5

Please provide us with feedback regarding your experience during the activity: *

Please use the scale: 1=Strongly Disagree, 2=Disagree, 3=Neutral, 4=Agree, 5= Strongly Agree

	1	2	3	4	5
Overall, I was satisfied with this program	Overall, I was satisfied with this program - 1	Overall, I was satisfied with this program - 2	Overall, I was satisfied with this program - 3	Overall, I was satisfied with this program - 4	Overall, I was satisfied with this program - 5
Overall, the content was relevant to my practice	Overall, the content was relevant to my practice - 1	Overall, the content was relevant to my practice - 2	Overall, the content was relevant to my practice - 3	Overall, the content was relevant to my practice - 4	Overall, the content was relevant to my practice - 5
The information presented was without promotional or commercial bias	The information presented was without promotional or commercial bias - 1	The information presented was without promotional or commercial bias - 2	The information presented was without promotional or commercial bias - 3	The information presented was without promotional or commercial bias - 4	The information presented was without promotional or commercial bias - 5
The information presented was scientifically rigorous and evidence based	The information presented was scientifically rigorous and evidence based - 1	The information presented was scientifically rigorous and evidence based - 2	The information presented was scientifically rigorous and evidence based - 3	The information presented was scientifically rigorous and evidence based - 4	The information presented was scientifically rigorous and evidence based - 5
The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A)	The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A) - 1	The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A) - 2	The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A) - 3	The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A) - 4	The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A) - 5
The information presented promoted improvements or quality in health care	The information presented promoted improvements or quality in health care - 1	The information presented promoted improvements or quality in health care - 2	The information presented promoted improvements or quality in health care - 3	The information presented promoted improvements or quality in health care - 4	The information presented promoted improvements or quality in health care - 5
The quality of the educational process was satisfactory and appropriate	The quality of the educational process was satisfactory and appropriate - 1	The quality of the educational process was satisfactory and appropriate - 2	The quality of the educational process was satisfactory and appropriate - 3	The quality of the educational process was satisfactory and appropriate - 4	The quality of the educational process was satisfactory and appropriate - 5
The format of the discussion was relevant and enhanced my knowledge of the subject	The format of the discussion was relevant and enhanced my knowledge of the subject - 1	The format of the discussion was relevant and enhanced my knowledge of the subject - 2	The format of the discussion was relevant and enhanced my knowledge of the subject - 3	The format of the discussion was relevant and enhanced my knowledge of the subject - 4	The format of the discussion was relevant and enhanced my knowledge of the subject - 5
The format of the discussion was relevant and enhanced my competence to treat patients with Cystic Fibrosis	The format of the discussion was relevant and enhanced my competence to treat patients with Cystic Fibrosis - 1	The format of the discussion was relevant and enhanced my competence to treat patients with Cystic Fibrosis - 2	The format of the discussion was relevant and enhanced my competence to treat patients with Cystic Fibrosis - 3	The format of the discussion was relevant and enhanced my competence to treat patients with Cystic Fibrosis - 4	The format of the discussion was relevant and enhanced my competence to treat patients with Cystic Fibrosis - 5
The faculty/speakers were knowledgeable and presented the information clearly	The faculty/speakers were knowledgeable and presented the information clearly - 1	The faculty/speakers were knowledgeable and presented the information clearly - 2	The faculty/speakers were knowledgeable and presented the information clearly - 3	The faculty/speakers were knowledgeable and presented the information clearly - 4	The faculty/speakers were knowledgeable and presented the information clearly - 5

How often do you currently do each of the following *

	Never	Not Often	Sometimes	Often	Always	N/A
Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis	Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis - Never	Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis - Not Often	Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis - Sometimes	Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis - Often	Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis - Always	Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis - N/A
Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment	Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment - Never	Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment - Not Often	Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment - Sometimes	Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment - Often	Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment - Always	Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment - N/A
Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype	Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype - Never	Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype - Not Often	Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype - Sometimes	Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype - Often	Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype - Always	Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype - N/A

How often do you plan to do each of the following *

	Never	Not Often	Sometimes	Often	Always	N/A
Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis	Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis - Never	Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis - Not Often	Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis - Sometimes	Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis - Often	Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis - Always	Develop new strategies to manage multiple clinical manifestations in patients with cystic fibrosis - N/A
Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment	Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment - Never	Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment - Not Often	Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment - Sometimes	Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment - Often	Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment - Always	Recognize the changes in lung pathophysiology after initiating genetically-targeted pharmacotherapies into patient treatment - N/A
Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype	Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype - Never	Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype - Not Often	Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype - Sometimes	Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype - Often	Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype - Always	Recognize the degree of pulmonary dysfunction can be highly variable, even among individuals with the same genotype - N/A

What barriers do you see regarding making a change in your practice?

Please rate each faculty on his/her overall teaching ability and overall knowledge and level of expertise regarding the subject *

	Poor	Fair	Good	Very Good	Excellent
Susanna A. McColley, MD (Program Chair)	Susanna A. McColley, MD (Program Chair) - Poor	Susanna A. McColley, MD (Program Chair) - Fair	Susanna A. McColley, MD (Program Chair) - Good	Susanna A. McColley, MD (Program Chair) - Very Good	Susanna A. McColley, MD (Program Chair) - Excellent
Jane Davies, MD	Jane Davies, MD - Poor	Jane Davies, MD - Fair	Jane Davies, MD - Good	Jane Davies, MD - Very Good	Jane Davies, MD - Excellent
Felix Ratjen, MD PhD	Felix Ratjen, MD PhD - Poor	Felix Ratjen, MD PhD - Fair	Felix Ratjen, MD PhD - Good	Felix Ratjen, MD PhD - Very Good	Felix Ratjen, MD PhD - Excellent
Manu Jain, MD	Manu Jain, MD - Poor	Manu Jain, MD - Fair	Manu Jain, MD - Good	Manu Jain, MD - Very Good	Manu Jain, MD - Excellent

Please provide details on any additional comments related to this activity

Elsevier CME

New Insights into Disease Progression for the CFTR Modulator-Treated Cystic Fibrosis Patient (Live)

Evaluation

Credit

Certificate

Course navigation

You are here

New Insights into Disease Progression for the CFTR Modulator-Treated Cystic Fibrosis Patient (Live)

Evaluation

Evaluation

Credit

Certificate

Course navigation